Cargando…

The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease

BACKGROUND: Graves’ disease (GD) is one of the most common autoimmune thyroid diseases (AITDs) in humans, and thyrotropin receptor antibody (TRAb) is a characterized autoantibody in GD. The use of radioactive iodine therapy (RAI) for GD treatment is increasing. OBJECTIVES: We studied the biological...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Ya, Du, Wen-Hua, Zhang, Cao-Xu, Zhao, Shuang-Xia, Song, Huai-Dong, Gao, Guan-Qi, Dong, Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630916/ https://www.ncbi.nlm.nih.gov/pubmed/34847904 http://dx.doi.org/10.1186/s12902-021-00905-4

Ejemplares similares

Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres
por: Shahida, Bushra, et al.
Publicado: (2021)

Thymic Involution After Radioiodine Therapy for Graves Disease: Relationships With Serum Thyroid Hormones and TRAb
por: Jinguji, Megumi, et al.
Publicado: (2017)

SAT462 TSI Versus TRAb In The Diagnosis Of Grave’s Disease
por: Ibrahim, Katherine, et al.
Publicado: (2023)

RhoA with Associated TRAb or FT3 in the Diagnosis and Prediction of Graves' Ophthalmopathy
por: Zhao, Sidi, et al.
Publicado: (2022)

Serum and thyroid tissue level of let-7b and their correlation with TRAb in Graves’ disease
por: Chen, Xinxin, et al.
Publicado: (2018)

The Effect of Inactivated SARS-CoV-2 Vaccines on TRAB in Graves’ Disease
por: Huang, LingHong, et al.
Publicado: (2022)

Thyrotropin Receptor Antibody (TRAb)-IgM Levels Are Markedly Higher Than TRAb-IgG Levels in Graves' Disease Patients and Controls, and TRAb-IgM Production Is Related to Epstein–Barr Virus Reactivation
por: Kumata, Keisuke, et al.
Publicado: (2016)

The Potential Link between Gut Microbiota and Serum TRAb in Chinese Patients with Severe and Active Graves' Orbitopathy
por: Shi, Ting-Ting, et al.
Publicado: (2019)

Age moderates the associations between TRAbs, free T3 and outcomes of Graves’ disease patients with radioactive iodine treatment
por: Lu, Lusi, et al.
Publicado: (2020)

Evaluation of TRAb and TSI Leves and Thyroid Function in Pregnant Women With Graves’ Disease and Newborn: Preliminary Data
por: Negri, Maurício Massucati, et al.
Publicado: (2021)

Radioiodine Thyroid Ablation in Graves’ Hyperthyroidism: Merits and Pitfalls
por: Nwatsock, J. F., et al.
Publicado: (2012)

Post-radioiodine management of patients with Graves' disease
por: Collins, K, et al.
Publicado: (2012)

Radioiodine therapy and Graves’ disease – Myths and reality
por: Plazinska, Maria Teresa, et al.
Publicado: (2020)

Radioiodine Therapy of Graves' Disease and the Uptake Paradox
por: Malapure, Sumeet Suresh, et al.
Publicado: (2020)

Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation
por: Silvestre, Ramona A., et al.
Publicado: (2021)

Sampling trabecular meshwork using TrabEx+
por: Ramjiani, Vipul, et al.
Publicado: (2021)

Radioiodine Therapy-Induced Conversion of Toxic Adenoma to Graves’ Disease
por: Rehman, Anis, et al.
Publicado: (2020)

Should radioiodine now be first line treatment for Graves’ disease?
por: Okosieme, Onyebuchi E., et al.
Publicado: (2020)

Association of the CTLA4 Gene with Graves' Disease in the Chinese Han Population
por: Zhao, Shuang-Xia, et al.
Publicado: (2010)

TSH Receptor Antibodies (TRAb) Assay: An Underutilized Test in India
por: Jacob, Jubbin Jagan
Publicado: (2022)

A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism
por: Doi, Suhail AR, et al.
Publicado: (2001)

Radioiodine therapy in patients with Graves’ disease and the effects of prior carbimazole therapy
por: Karyampudi, Arun, et al.
Publicado: (2014)

Acute effects of radioiodine therapy on the voice and larynx of basedow-graves patients
por: Isolan-Cury, Roberta Werlang, et al.
Publicado: (2015)

Worsening of pretibial myxedema following radioiodine treatment for hyperthyroid Graves’ disease
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2023)

Myopathy Associated with Acute Hypothyroidism following Radioiodine Therapy for Graves Disease in an Adolescent
por: Benavides, Valeria C., et al.
Publicado: (2010)

Primary autoimmune thrombocytopenia and co-existing Graves’ disease: Role of radioiodine-131
por: Jung, Rayamajhi Sampanna, et al.
Publicado: (2014)

Comparison of Fixed versus Calculated Activity of Radioiodine for the Treatment of Graves Disease in Adults
por: Canto, Abigail U., et al.
Publicado: (2016)

Prognostic factor analysis in 325 patients with Graves’ disease treated with radioiodine therapy
por: Yang, Danrong, et al.
Publicado: (2018)

Graves disease following radioiodine therapy for toxic adenoma: Clinical case report
por: Shen, Guohua, et al.
Publicado: (2017)

Pattern of presentation of Graves’ disease and response to radioiodine therapy in South African men
por: Onimode, Yetunde Ajoke, et al.
Publicado: (2018)

Radioiodine treatment for graves’ disease: a 10-year Australian cohort study
por: Fanning, Erin, et al.
Publicado: (2018)

Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of (131)I during radioiodine therapy of Graves’ disease
por: Happel, C., et al.
Publicado: (2021)

Candidate gene associations reveal sex‐specific Graves’ disease risk alleles among Chinese Han populations
por: Yan, Chen‐Yan, et al.
Publicado: (2020)

Extremely high doses of radioiodine required for treatment of Graves’ hyperthyroidism: a case report
por: Neto, Arnaldo Moura, et al.
Publicado: (2009)

Changes in the Properties of the Thyrotropin Receptor Antibody in Patients with Graves’ Disease after Radioiodine Treatment
por: Cho, Bo Youn, et al.
Publicado: (1990)

Graves Disease Induced by Radioiodine Therapy for Toxic Nodular Goiter: A Case Report
por: Yürekli, Yakup, et al.
Publicado: (2015)

Time course of Graves’ orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer
por: Louvet, Camille, et al.
Publicado: (2016)

Analysis of risk factors of rapid thyroidal radioiodine-131 turnover in Graves’ disease patients
por: Zhang, Ruiguo, et al.
Publicado: (2017)

Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study
por: Lanzolla, Giulia, et al.
Publicado: (2021)

SAT-555 Cytotoxicity of Epstein-Barr Virus Reactivation-Induced TRAb-IgM to Thyrocytes
por: Nagata, Keiko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7olld8nlrcfuqovdu0d2lao0b0